Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from BriaCell Therapeutics ( (TSE:BCT) ).
BriaCell Therapeutics reported an 11‑month sustained complete resolution of a lung metastasis in a 78‑year‑old patient with hormone receptor–positive, HER2‑negative metastatic breast cancer treated with its personalized off‑the‑shelf immunotherapy Bria‑OTS in a Phase 1/2a study. The patient, who had failed multiple prior treatments, showed 100% disappearance of a lung tumor after four doses of Bria‑OTS monotherapy, with the response repeatedly confirmed over nearly a year, no treatment‑limiting toxicities observed, and stable disease at other evaluable sites; BriaCell has completed the Phase 1 dose escalation and is now advancing the Phase 2a dose‑expansion stage combining Bria‑OTS with an immune checkpoint inhibitor, a step that could strengthen its position in the metastatic breast cancer treatment landscape and underscore the platform’s potential safety and efficacy for patients with limited options.
The most recent analyst rating on (TSE:BCT) stock is a Sell with a C$9.50 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
The score is driven primarily by weak financial performance (pre-revenue, expanding losses, and heavy cash burn despite no debt), reinforced by bearish technicals (price below key moving averages and negative MACD). Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, with a particular emphasis on metastatic and recurrent breast cancer. Its lead platform, Bria-OTS, is an off-the-shelf personalized immunotherapy derived from the company’s Bria-IMT candidate and is being evaluated in a Phase 1/2a clinical trial that includes both monotherapy and combination cohorts with immune checkpoint inhibitors.
Average Trading Volume: 6,128
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$18.88M
See more data about BCT stock on TipRanks’ Stock Analysis page.